- Home
- KNSA
as 10-28-2025 4:00pm EST
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.
| Founded: | 2015 | Country: | United Kingdom |
| Employees: | N/A | City: | LONDON |
| Market Cap: | 2.6B | IPO Year: | 2018 |
| Target Price: | $46.86 | AVG Volume (30 days): | 454.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.47 | EPS Growth: | N/A |
| 52 Week Low/High: | $17.82 - $42.05 | Next Earning Date: | 10-28-2025 |
| Revenue: | $597,973,000 | Revenue Growth: | 55.68% |
| Revenue Growth (this year): | 53.93% | Revenue Growth (next year): | 25.06% |
Stock Insider Trading Activity of Kiniksa Pharmaceuticals Ltd. (KNSA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Patel Sanj K | KNSA | CHAIRMAN & CEO | Oct 22 '25 | Sell | $38.83 | 97,390 | $3,781,653.70 | 111,794 | |
| Patel Sanj K | KNSA | CHAIRMAN & CEO | Oct 21 '25 | Sell | $38.77 | 39,331 | $1,524,862.87 | 111,794 | |
| Patel Sanj K | KNSA | CHAIRMAN & CEO | Oct 20 '25 | Sell | $39.07 | 121,248 | $4,717,015.02 | 111,794 | |
| Megna Michael R | KNSA | CHIEF ACCOUNTING OFFICER | Oct 20 '25 | Sell | $39.02 | 50,490 | $1,962,781.45 | 40,281 | |
| Tessari Eben | KNSA | CHIEF OPERATING OFFICER | Oct 14 '25 | Sell | $37.82 | 12,368 | $465,843.22 | 29,237 | |
| Tessari Eben | KNSA | CHIEF OPERATING OFFICER | Sep 29 '25 | Sell | $38.33 | 42,000 | $1,609,860.00 | 29,237 | |
| Tessari Eben | KNSA | CHIEF OPERATING OFFICER | Sep 15 '25 | Sell | $36.73 | 16,400 | $597,975.80 | 29,237 | |
| Tessari Eben | KNSA | CHIEF OPERATING OFFICER | Sep 5 '25 | Sell | $35.66 | 13,389 | $477,451.74 | 29,237 | |
| Tessari Eben | KNSA | CHIEF OPERATING OFFICER | Sep 4 '25 | Sell | $35.52 | 85,271 | $3,028,825.92 | 29,237 | |
| Moat Ross | KNSA | CHIEF CORP. & COMM. OFFICER | Sep 4 '25 | Sell | $35.31 | 3,523 | $124,397.13 | 9,415 |
Latest Kiniksa Pharmaceuticals Ltd. News
KNSA Breaking Stock News: Dive into KNSA Ticker-Specific Updates for Smart Investing
MT Newswires
12 days ago
Kiniksa Pharmaceuticals Says Pericarditis Treatment Candidate Got US FDA Orphan Drug Designation
GlobeNewswire
12 days ago
Kiniksa Pharmaceuticals Announces U.S. Orphan Drug Designation for KPL-387 for the Treatment of Pericarditis
Zacks
13 days ago
Why Kiniksa Pharmaceuticals International, plc (KNSA) is Poised to Beat Earnings Estimates Again
Zacks
2 months ago
RAPP Stock Soars 62% in a Week on Meeting Phase II Epilepsy Study Goal
Zacks
2 months ago
TVTX Stock Soars as FDA Waives Advisory Committee for Filspari sNDA
Zacks
2 months ago
RARE Reports Positive Long-Term Data From Metabolic Disorder Study
MT Newswires
2 months ago
Kiniksa Pharmaceuticals International Insider Sold Shares Worth $3,506,278, According to a Recent SEC Filing
MT Newswires
2 months ago
Kiniksa Pharmaceuticals International Insider Sold Shares Worth $547,141, According to a Recent SEC Filing
Compare KNSA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "KNSA Kiniksa Pharmaceuticals Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.